ZyVersa Therapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13G/A filing with the Securities and Exchange Commission (SEC) on February 9, 2024. The amendment was filed by L1 Capital Global Opportunities Master Fund Ltd., indicating that as of December 31, 2023, they no longer hold more than 5% of ZyVersa's common stock, effectively ceasing to be a major shareholder. The filing was made under Rule 13d-1(b) and is based on the number of shares outstanding as reported in ZyVersa's Quarterly Report on November 10, 2023. The address of the principal business office of L1 Capital Global Opportunities Master Fund Ltd. is located in the Cayman Islands. The filing includes a certification by David Feldman, Director of L1 Capital, stating that the shares were not acquired for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13G/A filing with the Securities and Exchange Commission (SEC) on February 9, 2024. The amendment was filed by L1 Capital Global Opportunities Master Fund Ltd., indicating that as of December 31, 2023, they no longer hold more than 5% of ZyVersa's common stock, effectively ceasing to be a major shareholder. The filing was made under Rule 13d-1(b) and is based on the number of shares outstanding as reported in ZyVersa's Quarterly Report on November 10, 2023. The address of the principal business office of L1 Capital Global Opportunities Master Fund Ltd. is located in the Cayman Islands. The filing includes a certification by David Feldman, Director of L1 Capital, stating that the shares were not acquired for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.